Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
8.00
-0.33 (-3.96%)
At close: Dec 5, 2025, 4:00 PM EST
8.42
+0.42 (5.25%)
After-hours: Dec 5, 2025, 4:46 PM EST
Elicio Therapeutics Employees
Elicio Therapeutics had 32 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
32
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,433,031
Market Cap
139.80M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 32 | 0 | - |
| Dec 31, 2023 | 32 | 9 | 39.13% |
| Dec 31, 2022 | 23 | -1 | -4.17% |
| Dec 31, 2021 | 24 | 2 | 9.09% |
| Dec 31, 2020 | 22 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ELTX News
- 17 days ago - Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer - GlobeNewsWire
- 22 days ago - Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 4 weeks ago - Elicio Therapeutics: Running On Fumes, But A Definitive Readout Appears Imminent - Seeking Alpha
- 4 weeks ago - Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC - GlobeNewsWire
- 4 weeks ago - Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting - GlobeNewsWire
- 5 weeks ago - Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial - GlobeNewsWire
- 2 months ago - Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma - GlobeNewsWire
- 2 months ago - Elicio Therapeutics Reports Inducement Grants - GlobeNewsWire